---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-034674"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T16:40:29.212844+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024

## Summary
- FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).
- Product gross margin improved to 72% from 70%; expects 75-80% in 2024.
- STAR-T trial selected for Breakout Presentation at AATS (April 2024); FDA/Health Canada submission planned for H2 2024.
- Ended 2023 with $15.6M cash; cost cuts include 15% RIF; cash runway into Q4 2024.
- Entered India partnership with Eris Lifesciences; plan to launch PuriFi pump in 2024.

## SEC filing metadata
- accession: 0001104659-24-034674
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/tm248917d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-034674
- JSON: https://secwatch.observer/filing/0001104659-24-034674.json
- Plain text: https://secwatch.observer/filing/0001104659-24-034674.txt

## Key facts
- Earnings Releases
  Cytosorbents Corp reported quarter and year ended December 31, 2023 results: revenue $36.3 million.
  - Period: quarter and year ended December 31, 2023
  - Revenue: $36.3 million
  - Result: reported results
  source text: quarter and year ended December 31, 2023 and provides its 2024 outlook. Full Year 2023 Financial Results · 2023 Total Revenue, which includes Product Sales and Grant Income, was $36.3 million versus $34.7 million in 2022, an increase of approximately $1.7 million or 5% · Total product sales were $31.1 million in 2023 versus $29.4 million in 2022, an increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.